Introduction The association between primary hyperparathyroidism (1HPT) and cancer is debated. The present study was aimed to investigate the occurrence of neoplasia in 1HPT. Patients and methods All consecutive patients (n = 1750) referred to our “Osteoporosis and Metabolic Disease” outpatients clinic for osteoporosis or hypercalcemia were eligible for the study. The exclusion criteria were: the finding of osteoporosis and/or altered calcium-phosphorous metabolism in the context of investigations for malignancy, the presence of diseases known to influence the cancer risk and the heavy smoking habit. Eventually, 1606 patients (1407 females, 199 males) were enrolled. In all patients calcium-phosphorous metabolism, PTH and vitamin D levels were measured and the occurrence of cancer during the 10 years prior the study inclusion was recorded. Results One-hundred-sixty-three patients had 1HPT while 1443 had not. Patients with and without 1HPT were comparable for age and gender. In 1HPT patients the occurrence of all, breast, kidney and skin cancer was significantly higher (21.5%, 12.2%, 2.5%, 1.8%, respectively) than in patients without 1HPT (12.4%, 6.9%, 0.3%, 0.3%, p < 0.05 for all comparisons). The 1HPT presence was significantly associated with the occurrence of all neoplasia and of breast, skin and kidney neoplasia (odds ratio, 95% confidence interval, p value: 1.93, 1.27–2.92, 0.002; 1.93, 1.11–3.35, 0.002; 9.18, 2.16–38.8, 0.003; 8.23, 1.71–39.5, 0.008, respectively), after adjusting for age, gender (as appropriate), smoking habit and vitamin D levels. Conclusion During the 10 years prior the diagnosis of 1HPT, the occurrence of all, breast, skin and kidney neoplasia is increased.

Occurrence of malignant neoplasia in patients with primary hyperparathyroidism / S. Palmieri, L. Roggero, E. Cairoli, V. Morelli, A. Scillitani, I. Chiodini, C. Eller-Vainicher. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - 43(2017), pp. 77-82. [10.1016/j.ejim.2017.06.001]

Occurrence of malignant neoplasia in patients with primary hyperparathyroidism

S. Palmieri;E. Cairoli;V. Morelli;I. Chiodini
;
C. Eller-Vainicher
2017

Abstract

Introduction The association between primary hyperparathyroidism (1HPT) and cancer is debated. The present study was aimed to investigate the occurrence of neoplasia in 1HPT. Patients and methods All consecutive patients (n = 1750) referred to our “Osteoporosis and Metabolic Disease” outpatients clinic for osteoporosis or hypercalcemia were eligible for the study. The exclusion criteria were: the finding of osteoporosis and/or altered calcium-phosphorous metabolism in the context of investigations for malignancy, the presence of diseases known to influence the cancer risk and the heavy smoking habit. Eventually, 1606 patients (1407 females, 199 males) were enrolled. In all patients calcium-phosphorous metabolism, PTH and vitamin D levels were measured and the occurrence of cancer during the 10 years prior the study inclusion was recorded. Results One-hundred-sixty-three patients had 1HPT while 1443 had not. Patients with and without 1HPT were comparable for age and gender. In 1HPT patients the occurrence of all, breast, kidney and skin cancer was significantly higher (21.5%, 12.2%, 2.5%, 1.8%, respectively) than in patients without 1HPT (12.4%, 6.9%, 0.3%, 0.3%, p < 0.05 for all comparisons). The 1HPT presence was significantly associated with the occurrence of all neoplasia and of breast, skin and kidney neoplasia (odds ratio, 95% confidence interval, p value: 1.93, 1.27–2.92, 0.002; 1.93, 1.11–3.35, 0.002; 9.18, 2.16–38.8, 0.003; 8.23, 1.71–39.5, 0.008, respectively), after adjusting for age, gender (as appropriate), smoking habit and vitamin D levels. Conclusion During the 10 years prior the diagnosis of 1HPT, the occurrence of all, breast, skin and kidney neoplasia is increased.
Breast cancer; Malignancy; Primary hyperparathyroidism; Vitamin D; Adult; Aged; Aged, 80 and over; Female; Humans; Hyperparathyroidism, Primary; Italy; Logistic Models; Male; Middle Aged; Neoplasms; Parathyroid Hormone; Time Factors; Vitamin D; Internal Medicine
Settore MED/13 - Endocrinologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
s1-ln2561601695844769-1939656818Hwf-2009085232IdV56054485625616016PDF_HI0001.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 879.23 kB
Formato Adobe PDF
879.23 kB Adobe PDF Visualizza/Apri
1-s2.0-S0953620517302297-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 513.12 kB
Formato Adobe PDF
513.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/616008
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 11
social impact